185 related articles for article (PubMed ID: 18473793)
21. Small molecule inhibitors of STAT3 for cancer therapy.
Zhao M; Jiang B; Gao FH
Curr Med Chem; 2011; 18(26):4012-8. PubMed ID: 21824090
[TBL] [Abstract][Full Text] [Related]
22. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains.
Gunning PT; Katt WP; Glenn M; Siddiquee K; Kim JS; Jove R; Sebti SM; Turkson J; Hamilton AD
Bioorg Med Chem Lett; 2007 Apr; 17(7):1875-8. PubMed ID: 17336521
[TBL] [Abstract][Full Text] [Related]
23. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation.
Duan Z; Bradner JE; Greenberg E; Levine R; Foster R; Mahoney J; Seiden MV
Clin Cancer Res; 2006 Nov; 12(22):6844-52. PubMed ID: 17121906
[TBL] [Abstract][Full Text] [Related]
24. The Role of Grb2 in Cancer and Peptides as Grb2 Antagonists.
Ijaz M; Wang F; Shahbaz M; Jiang W; Fathy AH; Nesa EU
Protein Pept Lett; 2018 Feb; 24(12):1084-1095. PubMed ID: 29173143
[TBL] [Abstract][Full Text] [Related]
25. Identification of novel small molecules that inhibit STAT3-dependent transcription and function.
Kolosenko I; Yu Y; Busker S; Dyczynski M; Liu J; Haraldsson M; Palm Apergi C; Helleday T; Tamm KP; Page BDG; Grander D
PLoS One; 2017; 12(6):e0178844. PubMed ID: 28636670
[TBL] [Abstract][Full Text] [Related]
26. Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation.
Szelag M; Czerwoniec A; Wesoly J; Bluyssen HA
PLoS One; 2015; 10(2):e0116688. PubMed ID: 25710482
[TBL] [Abstract][Full Text] [Related]
27. Novel high-throughput screening system for identifying STAT3-SH2 antagonists.
Uehara Y; Mochizuki M; Matsuno K; Haino T; Asai A
Biochem Biophys Res Commun; 2009 Mar; 380(3):627-31. PubMed ID: 19285012
[TBL] [Abstract][Full Text] [Related]
28. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity.
Siddiquee K; Zhang S; Guida WC; Blaskovich MA; Greedy B; Lawrence HR; Yip ML; Jove R; McLaughlin MM; Lawrence NJ; Sebti SM; Turkson J
Proc Natl Acad Sci U S A; 2007 May; 104(18):7391-6. PubMed ID: 17463090
[TBL] [Abstract][Full Text] [Related]
29. Novel synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth.
Li X; Ma H; Li L; Chen Y; Sun X; Dong Z; Liu JY; Zhu W; Zhang JT
Oncogene; 2018 May; 37(18):2469-2480. PubMed ID: 29456240
[TBL] [Abstract][Full Text] [Related]
30. Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.
Mandal PK; Gao F; Lu Z; Ren Z; Ramesh R; Birtwistle JS; Kaluarachchi KK; Chen X; Bast RC; Liao WS; McMurray JS
J Med Chem; 2011 May; 54(10):3549-63. PubMed ID: 21486047
[TBL] [Abstract][Full Text] [Related]
31. Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain.
Qiu HY; Zhu X; Luo YL; Lin HY; Tang CY; Qi JL; Pang YJ; Yang RW; Lu GH; Wang XM; Yang YH
Sci Rep; 2017 Jun; 7(1):2863. PubMed ID: 28588262
[TBL] [Abstract][Full Text] [Related]
32. 4-Carbonyl-2,6-dibenzylidenecyclohexanone derivatives as small molecule inhibitors of STAT3 signaling pathway.
Ji P; Yuan C; Ma S; Fan J; Fu W; Qiao C
Bioorg Med Chem; 2016 Dec; 24(23):6174-6182. PubMed ID: 27816267
[TBL] [Abstract][Full Text] [Related]
33. Identification of Lead Compounds as Inhibitors of STAT3: Design, Synthesis and Bioactivity.
Botta A; Sirignano E; Popolo A; Saturnino C; Terracciano S; Foglia A; Sinicropi MS; Longo P; Di Micco S
Mol Inform; 2015 Oct; 34(10):689-97. PubMed ID: 27490969
[TBL] [Abstract][Full Text] [Related]
34. High-throughput thermofluor-based assays for inhibitor screening of STAT SH2 domains.
de Araujo ED; Manaswiyoungkul P; Israelian J; Park J; Yuen K; Farhangi S; Berger-Becvar A; Abu-Jazar L; Gunning PT
J Pharm Biomed Anal; 2017 Sep; 143():159-167. PubMed ID: 28600954
[TBL] [Abstract][Full Text] [Related]
35. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
[TBL] [Abstract][Full Text] [Related]
36. A novel non-phosphorylated potential antitumoral peptide inhibits STAT3 biological activity.
Dourlat J; Liu WQ; Sancier F; Edmonds T; Pamonsinlapatham P; Cruzalegui F; Garbay C
Biochimie; 2009 Aug; 91(8):996-1002. PubMed ID: 19470402
[TBL] [Abstract][Full Text] [Related]
37. A STAT inhibitor patent review: progress since 2011.
Lai PS; Rosa DA; Magdy Ali A; Gómez-Biagi RF; Ball DP; Shouksmith AE; Gunning PT
Expert Opin Ther Pat; 2015; 25(12):1397-421. PubMed ID: 26394986
[TBL] [Abstract][Full Text] [Related]
38. Alpha-Based Multiplexed Assay for Identifying SH2 Domain Antagonists.
Asai A; Takakuma K
Methods Mol Biol; 2017; 1555():351-356. PubMed ID: 28092042
[TBL] [Abstract][Full Text] [Related]
39. Structural basis for the binding of high affinity phosphopeptides to Stat3.
McMurray JS
Biopolymers; 2008; 90(1):69-79. PubMed ID: 18058821
[TBL] [Abstract][Full Text] [Related]
40. Identification and characterization of small molecule inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening.
Zhang M; Zhu W; Ding N; Zhang W; Li Y
Bioorg Med Chem Lett; 2013 Apr; 23(7):2225-9. PubMed ID: 23434226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
